E154 - (CME) The Efficacy and Safety of VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia
NEI Podcast
00:00
Dutetra Benazine - A Drug That Has to Be Traded
The percentage of patients who had to have a dose reduction because of an adverse event on du atece benazine was four %. Those on placiba was two%. Oh my. Very so a difference of two %, which is a number needed a harm of 50. It took 50 patients to be randomized to do ateca venazine versus placibo before you expect to encounter one additional patient who had to having a dose reduction due to an adverse event. So, very highly tolerable agent. And then the sitific profile for dutetra benazine was also very impressive, was it not? It was.
Transcript
Play full episode
